IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced results from the GATHER2 Phase 3 clinical trial,...

Related Keywords

Reno ,Nevada ,United States ,Arshadm Khanani ,Dhaval Desai ,Iveric Bio ,Clinical Research At Sierra Eye Associates ,Astellas Pharma Inc ,Drug Administration On ,European Medicines Agency ,Astellas Company ,Clinical Research ,Sierra Eye Associates ,Senior Vice President ,Chief Development Officer ,Drug Administration ,European Medicines ,Retinal Detachments ,Intraocular Pressuretransient ,Prescribing Informationfor ,Focus Area Approach ,